UBS Initiates Coverage On SAB Biotherapeutics with Buy Rating, Announces Price Target of $7
Benzinga Newsdesk 9 months ago
NewsPrice TargetInitiationAnalyst Ratings
UBS analyst Michael Yee initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Buy rating and announces Price Target of $7.
UBS analyst Michael Yee initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Buy rating and announces Price Target of $7.